Results 161 to 170 of about 2,929 (206)
Comparison of vonoprazan with different frequency Amoxicillin regimens in the treatment of Helicobacter pylori infections: A retrospective study. [PDF]
Medicine (Baltimore)Li Y +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Vonoprazan: A New Potassium-Competitive Acid Blocker
Journal of Pharmacy Technology, 2023Objective: To review the safety, efficacy, and tolerability of vonoprazan for the treatment of Helicobacter pylori infection in adults. Data Sources: A literature search was performed through PubMed using the following key terms: vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, H pylori, and gastrointestinal. Study Selection and Data
Erin Lyn St Onge, Bradley Phillips
exaly +3 more sources
Reactions Weekly
ABSTRACT Helicobacter pylori is the most common chronic bacterial infection worldwide. Because of the risk for chronic gastritis, peptic ulcer disease, and gastric malignancy, all patients with H. pylori should be treated.
Delaney, Provenza +1 more
+9 more sources
ABSTRACT Helicobacter pylori is the most common chronic bacterial infection worldwide. Because of the risk for chronic gastritis, peptic ulcer disease, and gastric malignancy, all patients with H. pylori should be treated.
Delaney, Provenza +1 more
+9 more sources
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved vonoprazan (Voquezna – Phathom), a potassium-competitive acid blocker, for healing and maintenance of healing of all grades of erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak ...
openaire +2 more sources
Vonoprazan: First Global Approval
Drugs, 2015Vonoprazan (Takecab(®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux,
openaire +2 more sources